Press releases

Date	Title	View
May 7, 2024	Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update	PDF Version
May 1, 2024	Caribou Biosciences to Participate in Upcoming Investor Conferences	PDF Version
April 24, 2024	Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	PDF Version
April 15, 2024	Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	PDF Version
April 4, 2024	Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	PDF Version
March 11, 2024	Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	PDF Version
March 5, 2024	Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting	PDF Version
February 15, 2024	Caribou Biosciences to Participate in Upcoming Investor Conferences	PDF Version
January 7, 2024	Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024	PDF Version